Marketresearchnews

Thursday, 25 February 2021

Healthcare Supply Chain Management Market Value Share, Supply Demand, Share And Value Chain analysis 2023

The global healthcare supply chain management market is expected to grow significantly over the forecast period. It is estimated that the global healthcare supply chain management market is expected to register a CAGR ~ 8.2 % during the forecast period from 2018 to 2023. Supply-chain management is a process which includes planning, design, execution, control, and monitoring flow of various goods and services to create competitive logistics infrastructure, increases net value, synchronizing demand and supply of goods to measure performance. The major driving factors of supply chain management in healthcare are increasing globalization, expanding business, fast product life cycle, increasing fragmentation in the healthcare industry, the high economy of scale and other. The other factors responsible to support the market are increasing customer demand, rising customization, growing capabilities of technology and other. However, factors like lack of awareness, low innovation, the high cost of maintenance and installation, issues of integration may restrain the growth of the market.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/5716

Healthcare Supply Chain Management Market Segmentation

The Healthcare supply chain management market has been segmented into models, functions, delivery mode, software, technology, and end users. The market, on the basis of models, has been segmented into, build-to-order, make-to-stock model, continuous replenishment model, chain assembly and others.

On the basis of function, Healthcare supply chain management market is sub-segmented into forecasting and planning, warehousing and distribution, inventory management and procurement, internal logistics and operations, reverse and extended logistics and others.

On the basis of delivery mode, Healthcare supply chain management market further segmented into on-premise, web-based, and others.

On the basis of software, Healthcare supply chain management market is sub-segmented into planning tools and execution tools. The planning tools are sub-segmented into forecasting and inventory management, supplier and vendor management, production and sales planning, others. Execution tools are further sub-segmented into warehouse management, order processing and status tracking, others. On the basis of technology, the market is sub-segmented into a barcode, radio frequency identification (RFID), global positioning system (GPS), internet of things and big data, others. On the basis of end users pharmaceutical and biotech companies, logistics companies and distributors, healthcare providers, and others.

Healthcare supply chain management market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Healthcare supply chain management market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.

The European healthcare supply chain management market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.

The healthcare supply chain management market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The Healthcare supply chain management market in the Middle East & Africa has been segmented into the Middle East and Africa.

Healthcare Supply Chain Management Market Key players

The major key players of the global healthcare supply chain management market include SAP (Germany), Infor (US), Oracle (US), GHX (US), TECSYS (Canada), McKesson (US), Manhattan Associates (US), Jump Technologies (US), JDA Software (US), and LogiTag Systems (Israel), Advocate Health Care (Murray, UT), and others.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/healthcare-supply-chain-management-market-5716

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Pulse Oximeters Market Value Share, Supply Demand, Share And Value Chain analysis 2023

The worldwide pulse oximeters market is predicted to grow at around 6.5 percent during the forecast period (2017 to 2023). Pulse oximeters are used to assess key medical parameters; like cardiac, pulse, and breathing rates. They are employed to analyze the health of patients during the detection of their illnesses or when they display symptoms.

These products are adopted across homes, healthcare settings, healthcare emergencies. Rising elderly populace, preference for home surveillance, and chronic illnesses are some of the factors that drive this industry. Apart from these, heart problems and obesity coupled with unhealthy living conditions can also contribute market sales in the near future.

Browse Sample of the Report @

@ https://www.marketresearchfuture.com/sample_request/5671

Bad eating choices and consumption of junk food are the probable factors, reported to cause heart ailments, hypertension, and diabetes. Both these factors augur well for the industry and propel its revenues. In addition to the above factors, consumer awareness regarding ‘state-of-the-art’ pulse oximeters is said to boost market growth.

On the other hand, the key factor which hinders the industry is the shortage of awareness about these devices across middle & low income families. Considering the overall scenario, the pulse oximeters market is set to attain remarkable growth from 2017 to 2023. This fact is credited to the wider presence of cardiac arrhythmias, ischemic ailments, sleep apnea, and some others.

Innovations in technologies have resulted in customer-friendly and enhanced devices, resulting in higher market demand. For example, back in 2015, a wireless fingertip oximeter was introduced that could operate through Bluetooth. The said device possesses low power and was directed at recognizing untimely-involvement patients suffering from COPD and other breathing disorders.

Scarcity of well-established reimbursement regulations and heavy medical expenses urge patients to select home care and the convenience that comes along with it. This factor raises the need for remote patient surveillance devices, again leading to the growth of pulse oximeters. Quick sanctions on novel products & services also go a long way in promoting this market.

The global industry is experiencing constant mergers and acquisitions coupled with its other expansion strategies. Such an instance is the acquirement of a ‘Vital Signs’ company unit in 2013 by ‘CareFusion Corp.’ The deal was too good & reported to generate more incomes for specialized disposable businesses. The market is fragmented on the basis of products, applications, and regions.

Segments – Detailed Outlook

The pulse oximeters industry, in terms of products, consists of handheld, fingertip, and others. The various application sub-segments are medical amenities, hospitals, respiratory & cardiac centers, homecare, etc. Regions into which the market is split, comprise Asia Pacific, Europe, Americas, and the Middle East and Africa. Among products, handheld devices led the market.

The shares of handheld pulse oximeters were ascribed to massive ‘vital stats’ device usage and escalating surgical procedures. Additionally, the early diagnosis of life-long illnesses & disorders lowers more complexities and assists better treatments. Moreover, the identification of health risks are always beneficial in preventing other illnesses or relapses.

Also, heightened awareness about the significance of keeping patients under proper observation has positively impacted the market. Fingertip devices have also become more popular, with them being the most rapidly evolving sub-segment. Their non-invasive nature has helped them gain traction & patient convenience.

With respect to applications, medical amenities and hospitals maintained supremacy over the industry. The said fact was basically credited to multiple hypertension, heart arrhythmia, and COPD incidences. The global market was led by Americas. Europe was close behind, followed by Asia Pacific that was likely to be the fastest expanding market over the forecast period.

Competition, Players’ Strategies, and Recent News

The worldwide pulse oximeters market is fairly competitive, with various companies developing new products & services to remain ahead of one another. Product sanctions and mergers & acquisitions are some of the common strategies used by these players. Recently, a new oximeter, ‘Elera Starhealth’ was launched to make reading simple for the patients. It can operate non-stop for fifty hours & provide rapid & precise spot checks, as and when needed.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/pulse-oximeters-market-5671

About US:

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Home Healthcare Market Value Share, Supply Demand, Share And Value Chain analysis 2023

The global home healthcare market is anticipated to expand at 8.1% CAGR from 2017 to 2023 (forecast period), according to the latest report by Market Research Future (MRFR). Home healthcare is an increasing viable option being preferred by patients owing to increasing healthcare costs and the burgeoning geriatric population. Home healthcare provides a range of services including physical therapy, speech therapy, occupational therapy, and skilled nursing. The digitization of data has made it simpler for patients to contact physicians and clinicians and gain an accurate diagnosis from the comforts of their home.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/2030

Technological advances in healthcare and diagnosis equipment and government initiatives encouraging home healthcare are likely to fuel market demand in the forthcoming years. Taking a cue from patient demands, players such as Philips have launched wireless solutions. This is evident by the introduction of CarePoint 5.0, a easy-to-use nurse call system for senior citizens in assisted living facilities and bedridden patients recuperating at home. But concerns regarding patient safety can impede market growth.

Home Healthcare Market Overview

The report covers the latest trends affecting the market to provide the most accurate forecasts and predictions. By correlating the historical data with key market dynamics, our analysts can make highly astute projections. MRFR’s report includes a thorough analysis of the global home healthcare market segmented by product, service, software, and region. Trends and opportunities are highlighted coupled with the market share of companies as well as their valuation in the market. It analyzes new revenue sources for players and outlines the various strategies implemented by players.

Segment Overview

The global home healthcare market is segmented by product, service, software, and region. Products in the market include therapeutic and testing, screening, and monitoring products. The former is sub-segmented into dialysis equipment, respiratory therapy equipment, IV equipment, insulin delivery devices, wound care products, and others. On the other hand, the latter is segmented into holter and event monitors, pulse oximeters & heart rate monitors, sleep apnea monitors, blood glucose monitors, blood pressure monitors, cholesterol monitoring devices, and others.

Software discussed in the report designed to alleviate patient and hospital troubles include hospice solutions, telehealth solution, agency software, and clinical management systems. Based on services, the market is segmented into skilled nursing services, unskilled care services, respiratory therapy services, rehabilitation therapy services, infusion therapy services, and pregnancy care services.

The segments covered in the report are analyzed with respect to four major regions – North America, Europe, Asia Pacific (APAC), and the Middle East and Africa (MEA), with respective country-level market sizing. The definition and advantages of “home healthcare” is outlined in the report for a comprehensive understanding of the market. The report discusses in detail the various players and their respective strategies to enhance their value chain.

Competitive Landscape

Some of the key players in the home healthcare market include Koninklijke Philips N.V. (The Netherlands), F. Hoffmann-La Roche AG (Switzerland), A&D Company (Japan), Fresenius SE & Co KGaA (Germany), Abbott (U.S.), GE Healthcare (U.S.), McKesson Corporation (U.S.), B. Braun Melsungen AG (Germany), Becton Dickinson Company (U.S.), Omron Corporation (Japan), Medtronic PLC (U.S.), LG Electronics (South Korea), Kinnser Software (U.S.), Apple (U.S.), 3M (U.S.), and others. These players are engaged in partnerships to launch new products in the market and expand their consumer base.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/home-Healthcare-market-2030

About US:

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Chinese Fibromyalgia Market Segments, Opportunity, Growth And Forecast By End-Use Industry 2023

Fibromyalgia syndrome is a condition characterized by widespread musculoskeletal pain. Patients with fibromyalgia may also have muscle stiffness, increased sensitivity to pain, problems with mental processes, fatigue, irritable bowel syndrome (IBS), and others. As symptoms of fibromyalgia syndrome mimic other chronic diseases, therefore its diagnosis takes a long time. According to a study published in Arthritis Research & Therapy journal in 2017, in Taiwan, the risk of coronary heart disease in fibromyalgia patients was 47% higher than in the general population. For fibromyalgia to be diagnosed, the differential diagnosis is most commonly used. Other diagnostic procedures, such as laboratory evaluations are also used.

Notably, increasing cases of rheumatic diseases and growing geriatric population are the key factors driving the Chinese fibromyalgia market. According to the study published in Aging Clinical and Experimental Research in 2014, fibromyalgia syndrome can affect people of all age group, with the high prevalence in the elderly population as the geriatric population is more vulnerable towards pain, reduced mobility, and sleep disruption. In the general population, the prevalence of fibromyalgia increases by 2% at the age of 20 to 8% at the age of 70.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/5630

Growing awareness among the population, and rising incidences of traumatic stress and road accidents are also fueling the market growth. According to a study published in Pain Research and Management journal, in 2014, it was found that physical trauma is followed by fibromyalgia syndrome. In this study, conducted with a specific cohort of individuals involved in a motor vehicle collision, found that 8% of individuals developed widespread chronic pain. Widespread chronic pain characterizes fibromyalgia.

However, difficulty in diagnosis may hinder the growth of the market over the forecast period. Fibromyalgia can’t be easily confirmed as the condition is commonly expressed with many other accompanying chronic disorders such as rheumatic diseases, neurological disorders, mental health problems, and others

Chinese fibromyalgia market is expected to grow at a CAGR of 18.7% during the forecast period 2017-2022.

Intended Audience

Pharmaceutical Companies
Hospitals & Clinics
Research and Development (R&D) Companies
Government Research Institute
Academic Institutes and Universities

Segmentation

The Chinese fibromyalgia market is segmented on the basis of diagnosis, treatment, and end-user.

On the basis of the diagnosis, the market is classified into laboratory evaluation and presence of central sensitization.

On the basis of the treatment, the market is segmented into targeted treatment and symptomatic treatment.

On the basis of the end-users, the market is segmented into hospitals, clinics, diagnostic centers, and others.

Key Findings

The Chinese fibromyalgia market is expected to reach USD 3,079.1 million by 2022 at a CAGR of 18.7%
On the basis of the diagnosis, the laboratory evaluation segment is expected to command the largest market share of 77.2% over the review period, and it is also expected to grow at the fastest CAGR of 19.1% during the forecast period 2017-2022
On the basis of the treatment, the symptomatic treatment segment is expected to command the largest market share of 68.6% over the review period, and targeted treatment is expected to grow at the fastest CAGR of 19.2% during the forecast period 2017-2022
South Central China holds the largest share of the Chinese fibromyalgia market and is expected to reach USD 785.3 million by 2022
North China is the fastest growing market, which is expected to grow at a CAGR of 19.2% over the forecast period 2017-2022

Regional Analysis

South Central China accounted for the major share of the market owing to the rising prevalence of fibromyalgia in this region. Rising cases of chronic rheumatic diseases are also capable of fuelling the fibromyalgia market in China. Prevalence of rheumatoid arthritis is around 0.35%, with the significantly higher rate in Northern China as compared to the Southern part.

The rising healthcare expenditure is also propelling the growth of the market. In China, the total expenditure on health per capita in 2014 was USD 731, as per the World Health Organization (WHO) in 2015. The health expenditure in China grew at a rate of 11.6% per year, suggested by a study published in BMC Health Services Research journal in 2017. This rate is much faster than the growth of the country’s economy, i.e. 9.9% per year.

Key Players

Some of key the players in the market are Pfizer, GlaxoSmithKline, AstraZeneca, Roche, Astellas Pharma, Eli Lilly and Company, Johnson & Johnson Services, Inc., SANOFI, Bayer AG, AbbVie, ALLERGAN, Boehringer Ingelheim, Cephalon, Inc., Vertical Pharmaceuticals, Sunovion Pharms Inc, Jazz Pharmaceuticals, ABBOTT, NOVARTIS, and others.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/chinese-fibromyalgia-market-5630

About US:

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Sentinel Node Biopsy Market Segmentation Detailed Study With Forecast Up To 2023

A sentinel lymph node biopsy is a medical procedure, which involves identification, removal, and examination of the lymph node to verify the presence of cancer cells. Lymph nodes are a part of the lymphatic system which is found throughout the body and is connected to the lymph vessels. Breast cancer, melanoma, colon cancer, esophageal cancer, head and neck cancer, non-small cell lung cancer, stomach cancer, thyroid cancer are various indications for biopsy. The procedure helps the healthcare provider to determine the stage of cancer, its metastasis in order to plan a line of treatment for the patient.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/5582

Rising prevalence of various types of cancer such as breast cancer, melanoma, colon cancer and growing emphasis on women healthcare are the major drivers for the growth of the market. Additionally, increasing number of health problems women further fuel the market growth. Demand for diagnosis and treatment of breast cancer and the technologically advanced medical device is found to be increasing across the globe. Furthermore, increasing healthcare expenditure and overall growth of healthcare industry also influence the market growth. Extensive research in the field of reproductive health and diseases also boost the market. Increasing demand for new products and accessories with advent of technology in the healthcare industry also fuels the growth of the market across the globe. However, various factors restrained the market growth such as complications associated with the biopsy and unawareness among women.

The global sentinel node biopsy market is expected to grow at a CAGR of 5.1% during the forecast period.

Segments

The global sentinel node biopsy market is segmented on the basic product, indication, and end user.

On the basis of product, market is segmented into breast localization wire, tissue marker, gamma probe, drainage catheter, and others

On the basis of indication, the market is segmented into breast cancer, melanoma, colon cancer, esophageal cancer, and others.

On the basis of the end user, the market is segmented into hospitals & clinics, diagnostic centers, and others.

Intended Audience

Medical Device Manufacturers
Medical Device Suppliers
Medical Research Laboratories
Healthcare IT Companies
Research and Development (R&D) Companies
Market Research and Consulting Service Providers
Potential Investors

Regional Analysis of the Global Sentinel node biopsy Market

America captures the first position in the market for sentinel node biopsy whose market is driven by increasing number of women suffering from breast disorders and rising prevalence of breast cancer in the U.S. and Canada. Furthermore, the market is also driven by the availability of technologically advanced medical devices and quality care in healthcare institutes. In Americas, North America is the major market due to increasing number of market players offering biopsy devices and instruments. As per the American Cancer Society, in 2015, there were 231,840 new cases of breast cancer, and till March 2017, there were 3.1 million women with a history of breast cancer in the U.S. As per the National Cancer Institute, 2016, in the U.S. around 1,685,210 new cases of cancer were diagnosed and in 2014, around 15,780 children and adolescents ages 0 to 19 were diagnosed with cancer and 1,960 died of the disease.

In Europe, sentinel node biopsy market shows better growth opportunities governed by the ongoing research and development activities in the field of oncology. In Europe, there is an increasing demand for medical devices and availability of funds for research and development activities in the reproductive health. Germany acquires the first position the European market owing to an increasing demand for cancer diagnosis. France and U.K secure second and third position are respectively owing to the availability of tertiary care facilities in these countries and rising healthcare expenditure.

The Asia Pacific is the fastest growing region in the market whose growth is determined by the presence of highly skilled workforce and increasing demand for biopsy procedures in hospitals and specialty care centers. India and China exhibit enormous growth opportunities owing to ever increasing the prevalence of chronic diseases, increase in a number of women suffering for reproductive disorders, and increasing expenditure on surgical procedures industry by key players in developing economies throughout the Asia Pacific.

In the Middle East, Saudi Arabia and the United Arab Emirates are the major countries holding the largest share in the market. Increase in the number of specialty care services and rising demand for diagnosis of various types of cancer are the key drivers of the market. Africa exhibits slow growth owing to limited penetration of technology in this region and unawareness about sentinel node biopsy.

Browse More Details of the Report @

https://www.marketresearchfuture.com/reports/sentinel-node-biopsy-market-5582

Key Players in the Global Sentinel Node Biopsy Market

Some of the key players in this market are Devicor Medical Products, Inc., part of Leica Biosystems. (Germany), C. R. Bard, Inc. (U.S.), INTRAMEDICAL IMAGING LLC (U.S.), Hilfe Engineering Corporation (India), Surgic Eye (Germany), KUB Technologies, Inc. (U.S.), Navidea Biopharmaceuticals, Inc.(U.S.) and others.

About US:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Wednesday, 24 February 2021

Transarterial Chemoembolization (TACE) Market Projected to Witness Vigorous Expansion by 2025

Transarterial Chemoembolization (TACE) Market is expected to cross USD 2777.22 Million by 2025 at a CAGR of 8.57%.

The increasing prevalence of liver cancer is expected to drive the growth of the global transarterial chemoembolization (TACE) market. Hepatocellular carcinoma (HCC) is fifth cancer in terms of incidence and the second leading cause of cancer death for men worldwide. The incidence of HCC is highest in Asia and Africa.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/8564

Improvement in the reimbursement scenario is impacting the growth of the market. The cost of sorafenib is reimbursed by Taiwan’s National Health Insurance (NHI) administration with the TACE procedure. Moreover, Lipiodol is approved for National Health Insurance reimbursement for transcatheter arterial chemoembolization for HCC.

Segmentation

By Procedure Type

Conventional TACE: Conventional TACE dominated the Transarterial chemoembolization (TACE) market as it is one of the oldest procedures used in HCC cases. Conventional TACE involves the infusion of chemotherapeutic drugs blended with lipiodol and embolic agents into the cancer-feeding artery

DEB-TACE: This segment is expected to witness the fastest growth. DEB-TACE allows higher concentrations of drugs to the target tumor and lower systemic concentrations, compared with conventional TACE

By Indication

Unresectable HCC: TACE is a major treatment modality for unresectable HCC. The liver tumor which is not eligible for resection therapy given the extent of disease is considered as unresectable HCC

Early-Stage HCC: In case of early-stage HCC, TACE is recommended if resection or local ablation is not feasible

By Product Type

Chemotherapeutic Agents: Held the largest market share in 2018. Doxorubicin, cisplatin, and mitomycin are most commonly used in the TACE procedure. Doxorubicin is the most widely used chemotherapeutic agent for TACE of HCC. The dose of doxorubicin generally ranges from 30 to 75 mg/m2

Radiotherapeutic Agents: TACE with radiotherapeutic agents is the most expensive treatment for liver tumors.

Drug-eluting Particles: Drug-eluting beads have been imposed as novel drug-delivering agents for TACE. DC Beads is one of the most commonly used Drug-eluting beads. These beads are nonbiodegradable PVA microspheres, loaded with calibrated doxorubicin

By End-User

Hospitals & Clinics: It holds the largest market share that can be attributed to an increase in the number of patients afflicted by HCC, coupled with a rise in a number of hospitals, and quality care, and availability of skilled and qualified professionals.

Cancer Research Centers: This is the fastest-growing segment due to increasing research funding for the development of effective treatment of HCC

By Region

Americas: The region holds the largest share of the market. The market in the Americas has further been branched into North America and Latin America, with the North American market divided into the US and Canada.

Europe: The European transarterial chemoembolization (TACE) market has been classified as Western Europe and Eastern Europe. The Western European market has further been categorized as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.

Asia-Pacific: The market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The Asia-Pacific transarterial chemoembolization (TACE) market is projected to be the fastest-growing during the forecast period.

Middle East & Africa: The market in the Middle East & Africa has been divided into the Middle East and Africa.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/transarterial-chemoembolization-market-8564

About US:

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Seborrheic Dermatitis Treatment Market Poised to Witness a Significant Growth by 2025

Seborrheic Dermatitis Treatment Market is expected to cross USD 3.28 Billion by 2025 at a CAGR of 10.5 %.

Market Synopsis

Seborrheic dermatitis is a chronic inflammatory disorder that mostly affects the head and face. Primarily environmental, genetic, and general health problems are the cause of this disorder. The exact cause of seborrheic dermatitis remains unknown, but factors such as a change in hormone is the primary cause of this disease. It frequently affects people post-puberty. The prevalence of seborrheic dermatitis has been rising significantly in recent years. In the US alone, approximately 300 people are diagnosed with seborrheic dermatitis annually making it a reasonably common dermatological disorder worldwide. Some factors influencing the market growth are the rising awareness of personal hygiene, advancement in treatment options for seborrheic dermatitis, and growing awareness regarding seborrheic dermatitis.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/8499

The global seborrheic dermatitis treatment market is currently dominated by several market players. The key players are involved in product launches and strategic collaborations to strengthen their market positions.

Regional Analysis

The market has been divided, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas is expected to be the largest market owing to the increasing prevalence of seborrheic dermatitis and rising per capita healthcare expenditure. The seborrheic dermatitis treatment market in the Americas has further been branched into North America and Latin America, with the North American market divided into the US and Canada. The European seborrheic dermatitis treatment market has been categorized as Western Europe and Eastern Europe. The Western European market has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The seborrheic dermatitis treatment market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. Due to the increasing patient pool of skin disorder and raising awareness about seborrheic dermatitis, the market in Asia-Pacific is expected to be the fastest-growing. The seborrheic dermatitis treatment market in the Middle East & Africa has been divided into the Middle East and Africa.

Segmentation

The global seborrheic dermatitis treatment market has been segmented based on treatment type, route of administration, and end user.

The market, based on treatment type, has been divided into antifungal products, corticosteroid lotions, and sulfur products. Around 1.5 million Americans are diagnosed with various seborrheic dermatitis every year. The corticosteroid lotions segment is predicted to be the fastest-growing due to the rising prevalence of the disorder in the pediatric population.

The global seborrheic dermatitis treatment market has been segmented, on the basis of route of administration, oral, and topical. The oral segment is expected to hold the majority share of the market. Around 25 million adults are diagnosed with chronic seborrheic dermatitis every year, and most of them treated with the help of oral drugs. The topical segment is expected to be the fastest-growing due to its increasing use globally. It was estimated that around 1.3 million people in the US were afflicted with seborrheic dermatitis in 2018.

The end-user segments of the market are hospital pharmacies, retail pharmacies, and others. The hospital pharmacies segment is expected to hold the largest share of the market as these centers are the primary locations for patients receiving treatment and services.

Key Players

Some of the key players in the Global Seborrheic Dermatitis Treatment Market are Sonoma Pharmaceuticals (US), Merck (US), Hikma Pharmaceuticals (UK), Allen and Hanburys (UK), GlaxoSmithKline (UK), Bausch Health (Canada), Valent Pharmaceutical (UK), and West-Ward Pharmaceutical Corp. (US).

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/seborrheic-dermatitis-treatment-market-8499

About US:

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com